Suprainguinal Fascia Iliaca Block vs. Adductor Canal Block for Analgesia After Total Knee Arthroplasty
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: PCA.
- Who it may be relevant to
- Registry conditions: Arthroplasty, Knee Osteoarthritis. Basic parameters: 45 years — 100 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Comparing Suprainguinal Fascia Iliaca Block Versus Adductor Canal Block for Postoperative Pain Control Following Total Knee Arthroplasty;A Prospective, Double-Blind Controlled Trial
Overview
This study evaluates the analgesic efficacy and motor-sparing properties of ultrasound-guided Suprainguinal Fascia Iliaca Block (S-FIB) compared with Adductor Canal Block (ACB) in patients undergoing primary total knee arthroplasty (TKA). The main hypothesis is that ACB better preserves quadriceps muscle strength, allowing earlier functional mobilization, while providing comparable (non-inferior) analgesia to S-FIB.
Detailed description
Total knee arthroplasty is associated with severe postoperative pain requiring effective multimodal analgesia, and regional nerve blocks are integral to Fast-Track / ERAS (Enhanced Recovery After Surgery ) protocols. The Suprainguinal Fascia Iliaca Block (S-FIB) targets the anterior branches of the lumbar plexus (femoral, lateral femoral cutaneous, and obturator nerves) from a single high-volume injection, but proximal femoral spread can produce quadriceps motor weakness. The Adductor Canal Block (ACB) predominantly blocks the saphenous nerve, sparing motor function at the potential expense of less comprehensive analgesia.
Interventions
- Drug PCA
All patients receive standardized spinal anesthesia and postoperative intravenous PCA tramadol within a standardized multimodal regimen.
Primary outcome measures
- Postoperative Pain Intensity (NRS) [Time frame: Postoperative hours 24 hour]
Secondary outcome measures (4)
- Quadriceps Muscle Strength [Time frame: Postoperative hours 6 and 12.]
- Cumulative Opioid Consumption [Time frame: 24 and 48 hours postoperatively.]
- Time to First Mobilization [Time frame: Up to 48 hours postoperatively.]
- Quality of Recovery (QoR-15) [Time frame: Baseline (preoperative) and 24 hours postoperatively.]
Eligibility criteria
Inclusion criteria
- ASA Physical Status I, II, or III
- Scheduled for elective unilateral primary total knee arthroplasty
- Able to understand and operate the PCA device
- Written informed consent provided
Exclusion criteria
- Pre-existing lower-extremity neurological deficit or motor weakness (e.g., severe diabetic neuropathy)
- Chronic opioid use (>30 mg oral morphine equivalents/day for >3 months)
- Infection at the block site or systemic sepsis
- Coagulopathy or bleeding diathesis
- Allergy to local anesthetics or study medications
- Revision TKA or bilateral knee procedures
- Cognitive impairment or inability to perform mobility/pain assessments
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Non-randomized
- Model
- Parallel assignment
- Masking
- Double blind
- Primary purpose
- Treatment
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07739108 · TBEK 2026/05-20